Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite. We have heard enough names around…
We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) is set…
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is supposed to be acquired by a larger drug company. It is one of the biggest public merger rumors out there. At least that is the belief of Wall…
Markets opened a few ticks lower this morning after a poor report on new claims for unemployment benefits in the US (our coverage here). The report that pending home sales jumped 4.1%…
Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to acquire the company. With another small-cap to mid-cap biotech and emerging pharma company…
Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer from Bristol-Meyers…
The data is from a major union, and, therefore, may have a bias against chief executives. Numbers can be bent. The AFL-CIO reports that CEO pay rose 14% last year: According to…
After legal issues slowed their progress last year, foreclosures are about to increase. (Reuters) Time Warner Cable (NYSE: TWC) may end its deal with Current TV because of low ratings. (Reuters) The…
If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). News from Bloomberg is out that the company has rejected an offer to…
Anheuser-Busch InBev NV may buy China’s Kingway Brewery Holdings’ assets. (Reuters) The Department of Justice is expected to widen its probe of mortgage-backed securities. (Reuters) AT&T (NYSE: T) sets new standards that will impose penalties…
Gilead Sciences, Inc. (NASDAQ: GILD) has recovered from its pre-market lows on the devastating news that its Hepatitis C drug experienced close to a total failure in an arm of a late-stage…
The Pharmaceutical Research and Manufacturers of America (PhRMA) has spoken out against the new 2013 budget proposed by President Obama. PhRMA represents leading pharmaceutical research and biotechnology companies and some of the…
All three major US indexes opened higher this morning, but enthusiasm tapered off quickly and steadily, if not sharply. A drop in the number of new home sales and a smaller-than-expected rise…
It is not that often that investors get to clean up in a merger arbitrage spread any longer. The buyout of Inhibitex, Inc. (NASDAQ: INHX) by Bristol-Myers Squibb Company (NYSE: BMY) appears…
Jon C. Ogg The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp blows to…
